|01/27/15||Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma|
|US Submission Designed to Support Conversion From Accelerated to Full FDA Approval and Expansion of Current Approved Indication
EMA Grants Kyprolis Accelerated Assessment and Orphan Drug Designation
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Jan. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a Marketing A... |
|01/27/15||Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70|
|2014 GAAP EPS Were $6.70
2015 Revenues and Adjusted EPS Reaffirmed to be in the Range of $20.8-$21.3 Billion and $9.05-$9.40, Respectively
THOUSAND OAKS, Calif., Jan. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2014. Key results include:
For the fourth quarter, total revenues increased 6 percent to $5,331 million, with product sales growing at 8 percent. Adjusted EPS grew 19 percent to $2.16.
For the full ... |
|01/22/15||Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results|
|THOUSAND OAKS, Calif., Jan. 22, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2014 financial results on Tuesday, Jan. 27, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
|01/15/15||Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer|
|Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab
Separate Analysis of Phase 3 Trial Demonstrates no Differences in Quality of Life Between FOLFOX Regimens With or Without Vectibix
THOUSAND OAKS, Calif., Jan. 15, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix® (panitumumab) in combination with FOLFOX,... |